Quantcast

Latest Clinical trial Stories

2014-07-15 23:07:05

Announcing the Latest Version of the Market-Leading Clinical Conductor CTMS Rochester, NY (PRWEB) July 15, 2014 The Clinical Conductor CTMS team is proud to announce yet another major advancement in CTMS technology. With the latest release of Clinical Conductor, the market-leading CTMS again provides unparalleled advances in both features and functionality designed to give users even greater levels of increased efficiency and maximized profits. Most prominently seen in this release are...

2014-07-15 16:27:20

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Type 2 Diabetes Global Clinical Trials Review, H1, 2014https://www.reportbuyer.com/product/2160179/Type-2-Diabetes-Global-Clinical-Trials-Review-H1-2014.htmlType 2 Diabetes Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Type 2 Diabetes Global Clinical Trials Review, H1, 2014" provides data on the Type 2 Diabetes clinical trial scenario. This report...

2014-07-15 12:29:33

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Autism Global Clinical Trials Review, H1, 2014https://www.reportbuyer.com/product/2160177/Autism-Global-Clinical-Trials-Review-H1-2014.htmlAutism Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Autism Global Clinical Trials Review, H1, 2014" provides data on the Autism clinical trial scenario. This report provides elemental information and data relating to...

2014-07-15 12:28:31

Two drugs to be studied in North America and Europe in volunteers at high risk for disease COPENHAGEN, Denmark, July 15, 2014 /PRNewswire/ -- Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs--an active immunotherapy and an oral medication--can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for...

2014-07-15 04:22:22

ABERDEEN, Scotland and SINGAPORE, July 15, 2014 /PRNewswire/ -- TauRx Therapeutics Ltd [http://www.taurx.com ] today announced it has achieved its target enrolment of 833 subjects into one of its two ongoing multi-centre Phase III clinical trials of LMTX(TM) [http://taurx.com/lmtx-for-ad ], a tau aggregation inhibitor, for the treatment of Alzheimer's Disease [AD]. This placebo-controlled clinical trial (Protocol TRx-237-015 [http://taurx.com/015-clinical-study.html ]) has...

2014-07-14 23:04:05

Key Questions & Memorable Quotes from #eCongress Toronto, Canada (PRWEB) July 14, 2014 Throughout this past June 100s of mid-to-senior level executives from across the clinical trials space, representing 38 countries globally, registered for Xtalks 1st Annual eCongress webinar series entitled “Optimizing Patient Participation in Clinical Trials. Attract. Engage. Retain.” This well-attended eCongress kicked off with internationally renowned R&D expert, Ken Getz, of Tufts CSDD,...

2014-07-11 08:24:57

SYDNEY and BEDMINSTER, N.J., July 11, 2014 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) today provided feedback on its 9 July End-of-Review (EOR) meeting with the United States Food and Drug Administration (FDA). The meeting was held to discuss the feasibility and requirements for approving Moxduo, an immediate release Dual Opioid(®), for the treatment of moderate to severe acute pain. In advance of the meeting, QRxPharma outlined several questions to discuss with...

2014-07-10 10:28:40

Boston Children's Hospital Study calls for more focus on long-term outcomes in pediatric trials of drugs intended for chronic use Over the last 60 years, the U.S. Food and Drug Administration (FDA) approved 20 medications for attention deficit/hyperactivity disorder (ADHD) based on clinical trials that were not designed to study their long-term efficacy and safety or to detect rare adverse events, researchers at Boston Children's Hospital report today in PLOS ONE. The study highlights...

2014-07-09 23:06:47

Patented Smart Pill Bottle Company Will Use Capital to Scale the Product and Service New York, NY (PRWEB) July 09, 2014 AdhereTech (AdhereTech.com), a healthcare technology company that makes patented smart pill bottles to improve medication adherence and patient engagement, today announced its initial closing of $1.75 million in Series A financing. The round was led by undisclosed investors with a focus in healthcare. AdhereTech will use the investment to scale its service and meet the...

2014-07-09 16:28:10

Study calls for more focus on long-term outcomes in pediatric trials of drugs intended for chronic use BOSTON, July 9, 2014 /PRNewswire-USNewswire/ -- Over the last 60 years, the U.S. Food and Drug Administration (FDA) approved 20 medications for attention deficit/hyperactivity disorder (ADHD) based on clinical trials that were not designed to study their long-term efficacy and safety or to detect rare adverse events, researchers at Boston Children's Hospital report today in PLOS...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related